MX2018011881A - Sistema de administracion. - Google Patents

Sistema de administracion.

Info

Publication number
MX2018011881A
MX2018011881A MX2018011881A MX2018011881A MX2018011881A MX 2018011881 A MX2018011881 A MX 2018011881A MX 2018011881 A MX2018011881 A MX 2018011881A MX 2018011881 A MX2018011881 A MX 2018011881A MX 2018011881 A MX2018011881 A MX 2018011881A
Authority
MX
Mexico
Prior art keywords
oil
methods
active agent
organic solvent
optionally
Prior art date
Application number
MX2018011881A
Other languages
English (en)
Inventor
Hnat Thomas
Original Assignee
Smartech Topical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smartech Topical Inc filed Critical Smartech Topical Inc
Publication of MX2018011881A publication Critical patent/MX2018011881A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

De acuerdo con la presente descripción, se proporcionan formulaciones que comprenden: (a) al menos un agente activo; (b) un aceite y, opcionalmente, uespesante para este; (c) un disolvente orgánico y un espesante para este; y (d) un aceite y/o un potenciador de la penetración en la piel soluble en disolvente; en donde: dicha formulación comprende < 10 % en peso de agua; y dicha formulación forma opcionalmente un gel diluyente tixotrópico. También se proporcionan geles que comprenden aceite y un disolvente orgánico, métodos para prepararlos y métodos para la administración tópica de un agente activo a un sujeto que lo necesita.
MX2018011881A 2016-03-31 2017-03-31 Sistema de administracion. MX2018011881A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662316064P 2016-03-31 2016-03-31
PCT/US2017/025373 WO2017173269A1 (en) 2016-03-31 2017-03-31 Delivery system

Publications (1)

Publication Number Publication Date
MX2018011881A true MX2018011881A (es) 2018-12-17

Family

ID=59965231

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018011881A MX2018011881A (es) 2016-03-31 2017-03-31 Sistema de administracion.

Country Status (13)

Country Link
US (2) US11666531B2 (es)
EP (1) EP3435978A4 (es)
JP (1) JP2019510824A (es)
KR (1) KR20190003535A (es)
CN (1) CN109414405A (es)
AU (1) AU2017240680A1 (es)
BR (1) BR112018070140A2 (es)
CA (1) CA3019582A1 (es)
EA (1) EA201892156A1 (es)
MX (1) MX2018011881A (es)
PH (1) PH12018502036A1 (es)
SG (1) SG11201808231VA (es)
WO (1) WO2017173269A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018001429B1 (pt) 2015-08-13 2022-11-22 Basf Se Composição líquida não aquosa, método para a preparação da composição e método não terapêutico para controlar fungos fitopatogênicos e/ ou crescimento indesejado de plantas e/ ou ataque indesejado por insetos ou ácaros e/ ou para regular o crescimento de plantas
DE102016107563A1 (de) * 2016-04-22 2017-10-26 Sven Reichwagen Vitaminzubereitung
US11617727B2 (en) 2019-04-30 2023-04-04 Bayer Healthcare Llc Topical analgesic gel compositions
US20220378718A1 (en) 2019-05-28 2022-12-01 Tech Swerve Llc Penetrating topical pain relief compositions and methods of use
WO2020243352A1 (en) * 2019-05-28 2020-12-03 Tech Swerve Llc Penetrating topical pain relief compositions and methods of use
US11246872B2 (en) 2019-06-14 2022-02-15 Propella Therapeutics, Inc. Topical acyclovir formulations and uses thereof
US11026896B2 (en) * 2019-06-18 2021-06-08 Dyve Biosciences, Inc. Transdermal penetrant formulations containing cannabidiol
BR112022000767A2 (pt) 2019-07-16 2022-03-15 Donaghys Ltd Sistema de solvente transdérmico e métodos de uso
CA3155267A1 (en) 2019-11-06 2021-05-14 Thomas Hnat Topical formulations of cyclooxygenase inhibitors and their use
WO2021092340A1 (en) * 2019-11-07 2021-05-14 Amyris, Inc. Compositions and methods for delivering cannabinoids to skin
US11213467B2 (en) * 2019-11-07 2022-01-04 Amyris, Inc. Compositions and methods for delivering cannabinoids to skin
CN110917053A (zh) * 2019-12-06 2020-03-27 辉达生物医药（苏州）有限公司 一种抗炎组合物
CN113827547A (zh) * 2020-06-23 2021-12-24 南京清普生物科技有限公司 一种缓释制剂组合物
WO2022217147A1 (en) * 2021-04-09 2022-10-13 Rosenfeld Mark J Methods for improving cutaneous permeation of cannabinoids and fatty acid amides
CA3217501A1 (en) * 2021-05-05 2022-11-10 Thomas Hnat Topical naproxen formulations and their use

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63225312A (ja) * 1986-10-02 1988-09-20 Kao Corp 透明ないし半透明のジエリー状の化粧料
US5002938A (en) * 1988-03-21 1991-03-26 Bristol-Myers Squibb Company Antifungal gel formulations
US8980290B2 (en) * 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US7618651B2 (en) * 2004-06-24 2009-11-17 Idexx Laboratories Pharmaceutical compositions for drug delivery and methods of treating or preventing conditions using same
JP2006265153A (ja) * 2005-03-23 2006-10-05 Noevir Co Ltd ゲル組成物
CA2617934A1 (en) * 2005-08-05 2007-02-15 Nuvo Research Inc. Transdermal drug delivery formulation
BRPI0717769A2 (pt) * 2006-10-17 2013-11-05 Nuvo Res Formulação de gel, método para o tratamento da osteoartrite em um indivíduo sofrendo de dor articular, e, uso de diclofenac de sódio
KR101517494B1 (ko) * 2007-06-08 2015-05-04 트로이카 파마슈티칼스 리미티드 디클로페낙의 신규한 비수용성 국소 용액 및 이를 제조하는 과정
ES2562798T3 (es) * 2008-08-09 2016-03-08 Merck Patent Gmbh Uso de compuestos de indol como cosmético
WO2011049629A2 (en) * 2009-10-22 2011-04-28 Api Genesis, Llc Methods of making and using compositions comprising flavonoids
BR112012013331A2 (pt) * 2009-12-04 2016-03-01 Colgate Palmolive Co películas solúveis contendo elevadas concentrações de tensoativos não iônicos tais como polissorbatos para melhorar as altas cargas sólidas
WO2011143254A2 (en) * 2010-05-10 2011-11-17 Segetis, Inc. Personal care formulations containing alkyl ketal esters and methods of manufacture
US9504664B2 (en) * 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
PE20140936A1 (es) * 2011-05-03 2014-08-06 Aponia Lab Inc Composiciones transdermicas de ibuprofeno y metodos de uso de las mismas
US20140348905A1 (en) * 2011-12-12 2014-11-27 Leo Laboratories Limited Gel compositions
CN102652730B (zh) * 2012-03-29 2014-04-16 武汉华大药业有限公司 软膏基质、苦参绿茶软膏及其制备方法
US8822537B2 (en) * 2012-09-27 2014-09-02 Achelios Therapeutics, Inc. Topical ketoprofen composition
MX2015006390A (es) * 2012-11-21 2015-08-05 Topokine Therapeutics Inc Metodos y composiciones para incrementar localmente la grasa corporal.
CA3179312A1 (en) * 2013-03-15 2014-09-18 Vapogenix, Inc. Analgesic compositions comprising halogenated volatile compounds
US9012402B1 (en) * 2014-06-11 2015-04-21 James Blanchard Gel for topical delivery of NSAIDs to provide relief of musculoskeletal pain and methods for its preparation

Also Published As

Publication number Publication date
BR112018070140A2 (pt) 2019-02-05
EP3435978A1 (en) 2019-02-06
SG11201808231VA (en) 2018-10-30
AU2017240680A1 (en) 2018-11-15
CA3019582A1 (en) 2017-10-05
JP2019510824A (ja) 2019-04-18
KR20190003535A (ko) 2019-01-09
US20230310318A1 (en) 2023-10-05
PH12018502036A1 (en) 2019-07-15
EP3435978A4 (en) 2019-12-11
EA201892156A1 (ru) 2019-03-29
WO2017173269A1 (en) 2017-10-05
US11666531B2 (en) 2023-06-06
US20190046438A1 (en) 2019-02-14
CN109414405A (zh) 2019-03-01

Similar Documents

Publication Publication Date Title
PH12018502036A1 (en) Delivery system
MX2016011841A (es) Composiciones topicas de corticosteroides.
CO7240372A2 (es) Formulaciones farmacéuticas tópicas no acuosas
WO2014186742A3 (en) Anhydrous hydrogel composition
MX2018009824A (es) Composiciones para el cuidado personal.
BR112016029338A2 (pt) creme transdérmico
EA201890218A1 (ru) Ретиноидные композиции для местного применения
CL2020000220A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
WO2014121048A3 (en) Topical compositions and methods for making and using same
MX2022014634A (es) Metodos para la administracion linfatica de agentes activos.
WO2018141941A3 (en) Methods and systems for improving stability of pre-vapor formulations of e-vaping devices
WO2014177932A3 (en) Fertigation composition, use and system
MX2018005796A (es) Reduccion de la sensacion de picazon en la piel.
MY193312A (en) Topical formulation for promoting wound healing
PH12017501571A1 (en) Topical formulation
PH12018500910A1 (en) Novel method of use and compositions
WO2014169003A3 (en) Multi-functional composition for cosmetic formulations
AR113453A1 (es) Concentrados acuosos en suspensión a base de 2-[(2,4-diclorofenil)-metil]-4,4’-dimetil-3-isoxazolidinonas
MX361697B (es) Formulación transdérmica que contienen inhibidores de ciclooxigenasas (cox).
MX2022001736A (es) Formulaciones y tratamientos topicos.
WO2018105941A3 (ko) 탈모방지 또는 발모촉진용 주사용 조성물
CL2018003793A1 (es) Reducción de deriva de pulverización.
CL2020000221A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
WO2014137231A3 (en) Totarol extract formulations and uses thereof
TH154900A (th) สูตรผสมผ่านผิวหนังที่มีตัวยับยั้ง cox